Abion (Drug Discovery) Overview
- Year Founded
-
2007
- Status
-
Public
- Employees
-
51
- Stock Symbol
-
203400
- Investments
-
3
- Share Price
-
$2.52
- (As of Thursday Closing)
Abion (Drug Discovery) General Information
Description
ABION Inc is a biopharmaceutical company. It is primarily involved in the research and development new bio pharmaceutical drugs and companion diagnostics systems for the treatment of incurable diseases.
Contact Information
Website
www.abionbio.comCorporate Office
- 4th Floor, 43, Changeop-ro
- Sujeong-gu
- Seongnam, Gyeonggi 152-733
- South Korea
Corporate Office
- 4th Floor, 43, Changeop-ro
- Sujeong-gu
- Seongnam, Gyeonggi 152-733
- South Korea
Abion (Drug Discovery) Timeline
Abion (Drug Discovery) Stock Performance
As of 08-Oct-2026, Abion (Drug Discovery)’s stock price is $2.52. Its current market cap is $31.3M with 12.4M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.52 | $2.38 | $1.84 - $15.35 | $31.3M | 12.4M | 272K | -$1.65 |
Abion (Drug Discovery) Financials Summary
As of 30-Jun-2026, Abion (Drug Discovery) has a trailing 12-month revenue of $648K.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 43,874 | 148,859 | 150,244 | 140,649 |
| Revenue | 648 | 618 | 557 | 975 |
| EBITDA | (17,752) | (17,418) | (29,116) | (20,730) |
| Net Income | (19,535) | (20,422) | (31,794) | (22,342) |
| Total Assets | 41,988 | 55,952 | 43,302 | 34,666 |
| Total Debt | 6,091 | 6,275 | 11,688 | 11,724 |
Abion (Drug Discovery) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Abion (Drug Discovery) Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Abion (Drug Discovery) Patents
Abion (Drug Discovery) Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026225848-A1 | Anti-b7h3 antibody or antigen-binding fragment thereof, and use thereof | Pending | 21-Apr-2025 | ||
| WO-2026221359-A1 | Humanized antibody specific to claudin 4 and use thereof | Pending | 18-Apr-2025 | ||
| WO-2026205982-A1 | Fusion protein comprising antibody specifically binding to cldn3 and interferon-beta variant, and combination therapy using same | Pending | 25-Mar-2025 | ||
| WO-2026205975-A1 | Fusion protein comprising antibody specifically binding to trop2 and interferon-beta variant, and pharmaceutical composition comprising same | Pending | 25-Mar-2025 | ||
| AU-2024389329-A1 | Novel use of interferon epsilon | Pending | 28-Nov-2023 | A61P35/00 |
Abion (Drug Discovery) Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Abion (Drug Discovery) Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Abion (Drug Discovery) Investments (3)
Abion (Drug Discovery)’s most recent deal was a PIPE with Kpm Tech for . The deal was made on 26-Dec-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Kpm Tech | 26-Dec-2024 | PIPE | Industrial Chemicals | ||
| Vivozon | 05-Dec-2024 | Secondary Transaction - Private | Drug Discovery | ||
| Gyeonggi Housing and Urban Development (581.12 Square Meters of Land and Building in Seongnam) | 25-Apr-2023 | Corporate Asset Purchase | Buildings and Property |
Abion (Drug Discovery) ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Abion (Drug Discovery) FAQs
-
When was Abion (Drug Discovery) founded?
Abion (Drug Discovery) was founded in 2007.
-
Where is Abion (Drug Discovery) headquartered?
Abion (Drug Discovery) is headquartered in Seongnam, South Korea.
-
What is the size of Abion (Drug Discovery)?
Abion (Drug Discovery) has 51 total employees.
-
What industry is Abion (Drug Discovery) in?
Abion (Drug Discovery)’s primary industry is Drug Discovery.
-
Is Abion (Drug Discovery) a private or public company?
Abion (Drug Discovery) is a Public company.
-
What is Abion (Drug Discovery)’s stock symbol?
The ticker symbol for Abion (Drug Discovery) is 203400.
-
What is the current stock price of Abion (Drug Discovery)?
As of 08-Oct-2026 the stock price of Abion (Drug Discovery) is $2.52.
-
What is the current market cap of Abion (Drug Discovery)?
The current market capitalization of Abion (Drug Discovery) is $31.3M.
-
What is Abion (Drug Discovery)’s current revenue?
The trailing twelve month revenue for Abion (Drug Discovery) is $648K.
-
What is Abion (Drug Discovery)’s annual earnings per share (EPS)?
Abion (Drug Discovery)’s EPS for 12 months was -$1.65.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
